Study guide

2.2 Mechanical Circulatory Support

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

2.2 Mechanical Circulatory Support

Key Takeaways Explain This Topic AI

Intra-aortic balloon pumps (IABP) inflate during diastole to augment coronary perfusion and deflate during systole to decrease afterload.

Extracorporeal membrane oxygenation (ECMO) comes in two primary forms: V-V (respiratory support) and V-A (cardiopulmonary support).

Ventricular Assist Devices (VADs) unload the failing ventricle, providing continuous or pulsatile flow to maintain systemic perfusion.

Anticoagulation management is critical in patients with mechanical circulatory support devices to prevent circuit thrombosis.

Last updated: July 2026

Mechanical Circulatory Support (MCS) devices are utilized when the heart is unable to pump sufficient blood to meet the body's metabolic demands, leading to cardiogenic shock or severe heart failure. These devices range from temporary, percutaneous options to durable, surgically implanted pumps.

Intra-Aortic Balloon Pump (IABP)

The IABP is a temporary MCS device inserted percutaneously, typically through the femoral artery, and advanced into the descending aorta, positioning the tip just below the left subclavian artery.

Mechanism of Action: Counterpulsation

Diastolic Inflation: The balloon inflates at the onset of diastole (dicrotic notch on the arterial waveform). This forces blood backward to the aortic root, augmenting coronary artery perfusion pressure, and forward to the peripheral circulation.

Systolic Deflation: The balloon rapidly deflates just before the onset of left ventricular systole. This creates a sudden drop in aortic pressure, significantly reducing the afterload (resistance) against which the left ventricle must pump.

The net effect is an increase in myocardial oxygen supply (due to augmented coronary flow) and a decrease in myocardial oxygen demand (due to reduced afterload).

Indications and Contraindications

Indications: Cardiogenic shock, acute mitral regurgitation, unstable angina refractory to therapy, weaning from cardiopulmonary bypass.

Contraindications: Severe aortic insufficiency (inflation would worsen regurgitation), aortic dissection.

Impella Devices

The Impella is a percutaneous microaxial flow pump. It is inserted via the femoral or axillary artery, advanced across the aortic valve, and placed into the left ventricle.

Mechanism of Action

An internal motor draws blood from the left ventricle and expels it into the ascending aorta. This provides active, continuous forward flow (up to 2.5 to 5.5 L/min depending on the model), thereby directly unloading the left ventricle, reducing myocardial wall tension, and improving systemic perfusion.

Pharmacological Considerations

Impella devices require continuous purging with a dextrose solution containing an anticoagulant, most commonly unfractionated heparin, to prevent blood from entering the motor casing and to prevent thrombosis. The pharmacist must closely monitor systemic anticoagulation levels (e.g., ACT, aPTT, or anti-Xa) and adjust the systemic heparin infusion while accounting for the heparin delivered via the purge fluid.

Extracorporeal Membrane Oxygenation (ECMO)

ECMO provides prolonged cardiac and respiratory support. Blood is drained from the venous system, passed through a membrane oxygenator (where gas exchange occurs), and returned to the patient.

Veno-Venous (V-V) ECMO

Configuration: Blood is drained from a central vein and returned to a central vein (e.g., femoral vein to internal jugular vein, or a dual-lumen cannula in the IJ).

Support: Provides respiratory support only . It oxygenates the blood and removes CO2 but relies entirely on the patient's own heart to pump the oxygenated blood to the body.

Indications: Severe ARDS, bridge to lung transplant, severe pneumonia.

Veno-Arterial (V-A) ECMO

Configuration: Blood is drained from a central vein and returned to an artery (typically the femoral artery or ascending aorta).

Support: Provides both cardiac and respiratory support . It bypasses the heart and lungs, actively perfusing the systemic circulation.

Indications: Cardiogenic shock, failure to wean from cardiopulmonary bypass, cardiac arrest (E-CPR).

Anticoagulation in ECMO

The vast synthetic surface area of the ECMO circuit strongly activates the coagulation cascade. Systemic anticoagulation, typically with continuous intravenous unfractionated heparin, is mandatory. Alternatives like bivalirudin or argatroban are used in cases of Heparin-Induced Thrombocytopenia (HIT). Pharmacists play a vital role in titrating these high-risk drips, interpreting complex lab parameters, and managing bleeding complications.

Ventricular Assist Devices (VADs)

VADs are durable mechanical pumps surgically implanted to assist a failing ventricle. They can be Left VADs (LVADs), Right VADs (RVADs), or Biventricular (BiVADs).

Modern LVADs

Most modern LVADs (e.g., HeartMate 3) are continuous-flow centrifugal pumps. Because they provide continuous rather than pulsatile flow, patients often have a narrowed pulse pressure or even an absent palpable pulse. Blood pressure is measured via Doppler, assessing the Mean Arterial Pressure (MAP), with a target generally between 70-80 mmHg to ensure perfusion while preventing excessive afterload that could strain the pump or lead to bleeding strokes.

Complications and Pharmacotherapy

Thrombosis: VADs require lifelong anticoagulation, typically with warfarin (target INR 2.0-3.0) and antiplatelet therapy (aspirin).

Bleeding: The shear stress of continuous-flow pumps destroys von Willebrand factor, leading to an acquired von Willebrand syndrome and increasing the risk of severe gastrointestinal bleeding.

Infection: The percutaneous driveline is a common site for serious bacterial infections, necessitating prolonged antimicrobial therapy.

Right Heart Failure: Unloading the LV increases venous return to the right heart, which may precipitate acute right ventricular failure in vulnerable patients.